Steven Cohen increased his position by 53.95% in Amylin Pharmaceuticals Inc. (AMLN, Financial) at the average price of $13.54 on 07/05/2011, as reported in his latest 13G filings. He owns 7,089,049 shares. Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. The company has a market cap of $1.97 billion; its shares were traded at around $13.54 with and P/S ratio of 2.95.
Steven Cohen is a hedge fund manager who founded SAC Capital Advisors. The fund was founded in 1992 and currently has about $8 billion in assets under management. It employs about 800 people.
Carl Icahn owns 14,381,925 shares as of 03/31/2011, which accounts for 2.62% of the $6.24 billion portfolio of Icahn Capital Management LP. Edward Owens owns 1,357,200 shares as of 03/31/2011, which accounts for 0.08% of the $18.83 billion portfolio of Vanguard Health Care Fund.
SVP, Chief Medical Officer Orville G. Kolterman sold 13,750 shares of AMLN stock on 03/01/2011 at the average price of 15.02. Orville G. Kolterman owns at least 173,875 shares after this. The price of the stock has decreased by 9.85% since. Director James R. Gavin III sold 671 shares of AMLN stock on 01/18/2011 at the average price of 14.94. James R Gavin III owns at least 1,580 shares after this. The price of the stock has decreased by 9.37% since.
Amylin Pharmaceuticals recently reported financial results for the quarter ended March 31, 2011. The company reported total revenue of $152.7 million for the quarter ended March 31, 2011, which includes net product sales of $150.8 million and revenues under collaborative agreements of $1.9 million. Non-GAAP operating loss was $3.2 million for the quarter ended March 31, 2011, compared to $3.8 million for the same period in 2010. GAAP net loss was $37.3 million, or $0.26 per share, for the quarter ended March 31, 2011, compared to $38.2 million, or $0.27 per share, for the same period in 2010. Net loss excluding restructuring charges was $34.5 million, or $0.24 per share for the quarter ended March 31, 2011, compared to $38.2 million, or $0.27 per share for the same period in 2010.
"We continue to manage the business with operational discipline and ended the quarter in a strong financial position that led to reduced expenses and improved gross margins," said Mark G. Foletta, senior vice president of finance and chief financial officer at Amylin Pharmaceuticals. "We remain focused on our longer-term target of generating sustainable positive operating cash flow and, we believe, that the significant cost-savings we have realized over the past two years reflect our ability to efficiently manage our business and achieve this goal."
Steven Cohen is a hedge fund manager who founded SAC Capital Advisors. The fund was founded in 1992 and currently has about $8 billion in assets under management. It employs about 800 people.
Carl Icahn owns 14,381,925 shares as of 03/31/2011, which accounts for 2.62% of the $6.24 billion portfolio of Icahn Capital Management LP. Edward Owens owns 1,357,200 shares as of 03/31/2011, which accounts for 0.08% of the $18.83 billion portfolio of Vanguard Health Care Fund.
SVP, Chief Medical Officer Orville G. Kolterman sold 13,750 shares of AMLN stock on 03/01/2011 at the average price of 15.02. Orville G. Kolterman owns at least 173,875 shares after this. The price of the stock has decreased by 9.85% since. Director James R. Gavin III sold 671 shares of AMLN stock on 01/18/2011 at the average price of 14.94. James R Gavin III owns at least 1,580 shares after this. The price of the stock has decreased by 9.37% since.
Amylin Pharmaceuticals recently reported financial results for the quarter ended March 31, 2011. The company reported total revenue of $152.7 million for the quarter ended March 31, 2011, which includes net product sales of $150.8 million and revenues under collaborative agreements of $1.9 million. Non-GAAP operating loss was $3.2 million for the quarter ended March 31, 2011, compared to $3.8 million for the same period in 2010. GAAP net loss was $37.3 million, or $0.26 per share, for the quarter ended March 31, 2011, compared to $38.2 million, or $0.27 per share, for the same period in 2010. Net loss excluding restructuring charges was $34.5 million, or $0.24 per share for the quarter ended March 31, 2011, compared to $38.2 million, or $0.27 per share for the same period in 2010.
"We continue to manage the business with operational discipline and ended the quarter in a strong financial position that led to reduced expenses and improved gross margins," said Mark G. Foletta, senior vice president of finance and chief financial officer at Amylin Pharmaceuticals. "We remain focused on our longer-term target of generating sustainable positive operating cash flow and, we believe, that the significant cost-savings we have realized over the past two years reflect our ability to efficiently manage our business and achieve this goal."
